Skip to content
ea87720920e077e11cda96e09d7c04cb

CommBank cuts Afterpay’s grass

c72db755f466a0d1fef9231f1070b872.gif?r=540874719

Several European countries suspended the AstraZeneca COVID-19 vaccine, Afterpay met its newest Buy Now Pay Later rival, and Bitcoin soared past 62,000 US dollars this week.

Locally, the ASX closed lower on Friday and shed 0.87% for the week as the tech sector faced a widespread selloff on the back of rising inflation fears amongst investors in the US.

Australia’s unemployment rate fell to 5.3% for February, beating expectations of 6.3% as the economic recovery gains momentum.

Still, there is a bump in the road ahead with JobKeeper ending this month.

The week as a chart

S&P/ASX 200

cec06e2f93a4ba322afde526713e4d3b.png?r=1533487993

-0.87%

Want to see more charts?

03cee2c5d9cec4cdcff16a925f9a5bda

CommBank jumps on BNPL bandwagon

Competition in the Buy Now Pay Later sector heated up this week as the Commonwealth Bank of Australia unveiled its CommBank BNPL offering.

The new market entry aims to undercut Afterpay’s fees and will include customer credit checks - a step Afterpay has so far refused to take.

Want to see more?

These media summaries are available in the Grafa App.
Click here to download.

ed37805a538a74c2464b778e6da1345f

Which COVID-19 jab do investors prefer?

1cde4fac63e38fae37dee8a07787bee9.png?r=1711986827
  • Pfizer's first mover advantage has little impact on share price growth.
  • AstraZeneca moves in unison with Pfizer despite negative press.
  • Moderna’s share price soared 620% in the last 12-months.

US-based Moderna has experienced the highest share price growth of the big three pharmaceutical companies mass producing COVID vaccines over the last 12 months.

The smallest of the big three, Moderna’s share price has soared 453% over the last year from a low US$25.82 in March 2020 to as high as US$185.98/share in February 2021.

This has seen the company’s market capitalisation grow almost ten-fold to US$56.6 billion.

Despite its first mover advantage, Pfizer’s share price has traded in a measured range between a low of US$27.03/share and high at US$42.56/share over the last 12 months.

AstraZeneca’s share price has risen 22.3% and Pfizer’s share price has increased by 17.4%.

Know a mate who would like this? Forward it on.

620c98ffb2274c3d4194aa11586e0208